Spice up Crypto Trading in 2026 With This Exciting ETF
Emerging Segment Could Lift This Coinbase ETF in 2026
Direxion Ignites New ETFs To Fuel Bold Bets On Coinbase, Robinhood, Intel, Oracle
CONX Corp. Announces Acquisition of Red Technologies SAS
Delisting of Securities of CONX Corp.; Priveterra Acquisition Corp. II; Yield10 Bioscience, Inc.; Aesthetic Medical International Holdings Group Ltd.; Breeze Holdings Acquisition Corp.; Quadro Acquisition One Corp.; DermTech, Inc.; TRACON Pharmaceuticals, Inc.; eFFECTOR Therapeutics, Inc.; Dynatronics Corporation; and Canna-Global Acquisition Corp. from The Nasdaq Stock Market
OTC Markets Group Welcomes CONX Corp. to OTCQX
CONX Corp. Announces Closing of Initial Business Combination
CONX Corp. Announces Final Tender Offer Results
CONX Corp. Announces Change in Tender Offer Price to Complete Business Combination
CONX Corp. Announces Tender Offer to Complete Business Combination
CONX Files Proxy Statement for Stockholders to Vote on Extension of Completion Period; Discloses Preliminary Discussions Regarding Business Combination
Corgenix Receives FDA Authorization and WHO Listing for Emergency Use of Ebola Rapid Diagnostic Test
Corgenix Announces New Grants to Advance Work on Ebola Test Kit
Corgenix Signs Memorandum of Understanding Regarding Settlement of Litigation and Announces Plan to Adjourn Special Meeting to December 10
Corgenix Announces Preliminary Revenue and Net Loss Results for Quarter ended September 30, 2014
Corgenix Provides Update on Ebola Test Kit NIH Grant
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Corgenix Announces CE Mark Notification for TxBCardio™ Assay
Corgenix Reports Third Quarter Fiscal 2014 Financial Results
Corgenix to Host Conference Call to Discuss Third Quarter Results
Corgenix to Host Conference Call to Discuss Third Quarter Results
Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Corgenix to Host Conference Call to Discuss Second Quarter Results
Corgenix to Host Conference Call to Discuss Second Quarter Results
Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio™ Assay
Corgenix to Launch New Hepcidin-25 Product at the American Society of Hematology Annual Meeting
Corgenix Inks Collaborative Diagnostic Test Development Deal with Zalgen Labs
Corgenix Reports First Quarter Fiscal 2014 Financial Results
Corgenix Files Concurrent de novo 510(k) Pre-Market Notification for FDA Clearance of its Hyaluronic Acid (HA) Test Kit
Study: Aspirin Ineffective in 20 Percent of Heart Disease Patients
Corgenix to Host Conference Call to Discuss First Quarter Results
Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.
Corgenix Reports Fiscal 2013 Financial Results
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Corgenix Medical Corporation Announces New AtherOx® (Oxidized LDL Technology) License and Cooperation Agreement
Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility
Corgenix Teams Up with Strategic Partners at AACC Clinical Lab Expo 2013
Corgenix Announces Contract Manufacturing Agreement with EDP Biotech
Corgenix Announces Diagnostic Development Agreement with Lilly
Corgenix Reports Third Quarter Fiscal 2013 Financial Results
Corgenix Gains CE Mark for ReLASV® Antigen Rapid Test for Diagnosis of Lassa Fever
Corgenix to Host Conference Call to Discuss Third Quarter Results
Corgenix Expands Contract Services Business Unit
Corgenix Announces Initial Phase Completion of a Multi-Year Pivotal Clinical Trial of Rapid Test for Lassa Fever